Floatz logo

Fedratinib

Myeloproliferative Neoplasm, Not Otherwise Specified

University of WashingtonSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Myeloproliferative Neoplasm, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Ruxolitinib
University of Washington
Phase 2CCC
Decitabine
University of Washington
Phase 2CCC
Azacitidine
M.D. Anderson Cancer Center
Phase 1/2CCC
Pevonedistat
M.D. Anderson Cancer Center
Phase 1/2CCC
Venetoclax
M.D. Anderson Cancer Center
Phase 1/2CCC
Pacritinib
University of Washington
Phase 2CC

Same molecule, other indications

Fedratinib is also rated in:

acquired polycythemia veraDormant
CCC
Indicative ·
53 / 100
View asset →
primary myelofibrosisDormant
CCC
Indicative ·
53 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →